Fresenius SE & Co. KGaA Increases 2026 Earnings Guidance

Fresenius SE & Co. KGaA has revised its earnings guidance for fiscal year 2026 due to a robust performance in its core businesses, Fresenius Kabi and Fresenius Helios. The company now expects a 10% to 15% growth in core earnings per share, compared to the previous forecast of 5% to 10%.

In the second quarter of 2026, the Fresenius Group reported a 6% organic increase in revenue, amounting to €5,864 million. The Group’s EBIT, excluding special items, rose by 10% in constant currency to €719 million, improving the EBIT margin to 12.3%.

Despite the ongoing macroeconomic and geopolitical volatility, the company maintains an organic revenue growth expectation of 4% to 7% for the year 2026. However, the guidance does not factor in potential extreme scenarios in the healthcare sector.